Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)

NCT02562235 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02562235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02562235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 29, 2015
Completion date
May 15, 2028
Enrollment
24 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary